子類別 期刊論文 [327/330] 圖書 [1/1] 會議論文/會議摘要 [115/179] 鄰近社群 于重元 [19/19] 劉柯俊 [85/98] 劉滄梧 [119/125] 劉界元(2003-2010) [3/3] 夏和雄(1996-2012) [26/31] 夏興國 [51/54] 姜乃榕 [82/94] 常慧如 [39/44] 張俊彥 [234/254] 張光裕 [69/79] 張憶壽 [103/106] 張文祥 [52/53] 張書銘 [89/91] 彭汪嘉康(1996-2007) [120/126] 施能耀 [37/43] 李家惠 [29/29] 李岳倫 [48/49] 林素芳 [32/32] 楊奕馨 [41/42] 江士昇 [88/90] 沈哲宏 [14/16] 洪文俊 [88/88] 莊雙恩 [82/91] 蔡坤志 [32/34] 蔡慧珍 [66/71] 蘇勇曄 [40/40] 蘇振良 [24/25] 郭靜娟 [71/76] 陳尚鴻 [45/48] 陳振陽 [72/72] 陳美霞(2002-2009) [1/1] 陳詩政 [2/2] 陳雅雯 [38/39] 黃智興 [55/55] 黃道揚 [26/26] 丁兆治(2000-2004) [5/5] 其他 [464/471] 劉敏(1996-2007) [60/62] 劉玫英(2004-2006) [2/2] 吳成文(1996-2008) [53/55] 曾思文(1997-2007) [4/4] 李冠德(1997-2004) [4/6] 林景太(1999-2007) [5/5] 楊文光(1996-1999) [21/21] 王全正(1996-2003) [4/4] 莊聲宏(1997-2004) [11/11] 詹宗晃(2000-2008) [2/2] 賴基銘(2004-2008) [41/47] 阮麗蓉(2000-2006) [6/7] 陳俊叡(2003-2007) [6/6] 馬彥英(1997-1999) [1/1] 黃奇英(2005-2007) [9/10] 社群統計 近3年內發表的文件:74(14.51%) 含全文筆數:443(86.86%) 文件下載次數統計 下載大於0次:443(100.00%) 下載大於100次:426(96.16%) 檔案下載總次數:178043(3.32%) 最後更新時間: 2024-12-01 03:12 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati... Survival of advanced/recurrent gast... Topiramate suppresses peri-infarct ... A phase 1 study of biweekly nab-pac... Plain language summary of the FOENI... Outcomes of post-immunotherapy dura... Durvalumab or placebo plus gemcitab... Impact of previous S-1 treatment on... Chromatin remodeling-related PRDM1 ...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目276-300 / 510. (共21頁) << < 7 8 9 10 11 12 13 14 15 16 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2016-02	Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells	RNA. 2016 Feb;22(2):303-315.
2016-02	Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy	Oncology Research and Treatment. 2016 Feb;39(Suppl. 1):170.
2016-02	Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy	Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 134.
2016-02	Phase I trial of biweekly S-1, leucovorin, oxaliplatin, and gemcitabine (the SLOG regimen) in metastatic pancreatic adenocarcinoma (mPDAC)	Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 369.
2016-02	A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC)	Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract TPS482.
2016-02	Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy	Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 417.
2016-02	Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors	Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 745.
2016-01	Investigating the association between periodontal disease and risk of pancreatic cancer	Pancreas. 2016 Jan;45(1):134-141.
2016-01	S-1 with leucovorin for gastric cancer: How far can it go?	Lancet Oncology. 2016 Jan;17(1):12-14.
2016-01	A phase II study of sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric adenocarcinoma: The TCOG 3211 clinical trial	Medicine. 2016 Jan;95(3):Article number e2565.
2015-12-21	G9a orchestrates PCL3 and KDM7A to promote histone H3K27 methylation	Scientific Reports. 2015 Dec 21;5:Article number 18709.
2015-12	A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma-TCOG 3211 clinical trial	Journal of Gastroenterology and Hepatology. 2015 Dec;30(Suppl. S4):99.
2015-10	Epigenetic regulation in the carcinogenesis of cholangiocarcinoma	International Journal of Biochemistry and Cell Biology. 2015 Oct;67:110-114.
2015-10	Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells	Cancer Cell International. 2015 Oct;15:Article number 98.
2015-09	AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-kappaB activation	Leukemia and Lymphoma. 2015 Sep;56(9):2674-2682.
2015-09	The safety and efficacy of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan	European Journal of Cancer. 2015 Sep;51(Suppl. 3):S459.
2015-09	Expression of the Helicobater pylori CagA protein is closely associated with Helicobater pylori-dependence of early-stage high-grade gastric lymphoma	European Journal of Cancer. 2015 Sep;51(Suppl. 3):S662.
2015-08	Primary gastrointestinal stromal tumor of the liver in an anorectal melanoma survivor: A case report	Oncology Letters. 2015 Aug;10(4):2366-2370.
2015-08	The association between periodontal disease and pancreatic cancer	Cancer Research. 2015 Aug;75:Abstract number 871.
2015-07	Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review	Cancer Research and Treatment. 2015 Jul;47(3):343-361.
2015-06	Helicobacter pylori CagA translocation is closely associated with the expression of CagA-signaling molecules in low-grade gastric mucosa-associated lymphoid tissue lymphoma	American Journal of Surgical Pathology. 2015 Jun;39(6):761-766.
2015-06	Comprehensive analysis of the incidence and survival patterns of lung cancer by histologies, including rare subtypes, in the era of molecular medicine and targeted therapy: A nation-wide cancer registry-based study from Taiwan	Medicine. 2015 Jun;94(24):Article number e969.
2015-05	A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer	Annals of Oncology. 2015 May;26(5):943-949.
2015-05	Heterogeneous cell origin of helicobater pylori-dependent high-grade gastric lymphomas	Journal of Clinical Oncology. 2015 May;33(15, Suppl.):e19520.
2015-05	Randomized, phase III trial of adjuvant adeforvir vs. therapeutic lamivudine in post-operative BCLC stage 0 or A HBV-related HCC: The Taiwan Cooperative Oncology Group T1206 study	Journal of Clinical Oncology. 2015 May;33(15, Suppl.):4101.

顯示項目276-300 / 510. (共21頁) << < 7 8 9 10 11 12 13 14 15 16 > >> 每頁顯示[10|25|50]項目